Symbiox Investment & Trading Co. Ltd.

As of June 30, 2026, Symbiox Investment & Trading Co. Ltd. carries a market capitalization of 48.24M, placing it among publicly traded companies globally. Its enterprise value stands at 48.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Symbiox Investment & Trading Co. Ltd. has 30.92M shares outstanding.

As of June 30, 2026, Symbiox Investment & Trading Co. Ltd. trades at a trailing price-to-earnings ratio of 29.59.

As of June 30, 2026, Symbiox Investment & Trading Co. Ltd. trades at an EV/EBITDA multiple of 21.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.98 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 48.24M versus a market cap of 48.24M, with the gap driven by net debt and cash on the balance sheet.

Over the twelve months ended June 30, 2026, Symbiox Investment & Trading Co. Ltd. recorded 572,000.00 in income tax expense. That works out to an effective tax rate of 26.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.20M, leaving 1.63M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Symbiox Investment & Trading Co. Ltd.'s stock has declined approximately 39.92% over the past 52 weeks. The 50-day moving average sits at 1.87, while the 200-day moving average is 1.78.

Over the twelve months ended June 30, 2026, Symbiox Investment & Trading Co. Ltd. generated 14.00M in revenue and converted that into 1.63M in net income, yielding earnings per share of 0.05. EBITDA reached 2.22M, while operating income came in at 2.20M.

Over the twelve months ended June 30, 2026, Symbiox Investment & Trading Co. Ltd. posted a gross margin of 45.26, reflecting its pricing power and cost economics. The operating margin of 15.68 and net profit margin of 11.62 provide insight into operational efficiency.